Sorafenib and Piperine co-loaded PLGA nanoparticles: Development, characterization, and anti-cancer activity against hepatocellular carcinoma cell line

Saudi Pharmaceutical Journal, Journal Year: 2024, Volume and Issue: 32(5), P. 102064 - 102064

Published: April 7, 2024

Hepatocellular carcinoma (HCC) exhibits high mortality rates in the advanced stage (>90 %). Sorafenib (SORA) is a targeted therapy approved for treatment of HCC; however, reported response rate to such therapeutic suboptimal (<3%). Piperine (PIP) an alkaloid demonstrated exert direct tumoricidal activity HCC and improve pharmacokinetic profiles anticancer drugs including SORA. In this study, we developed strategy efficacy outcomes using PIP as add-on support first-line SORA biodegradable Poly (D, L-Lactide-co-glycolide, PLGA) nanoparticles (NPs). (both exhibit low aqueous solubility) were co-loaded into PLGA NPs (PNPs) stabilized with various concentrations polyvinyl alcohol (PVA). The PIP-loaded PNPs (SP-PNPs) characterized Fourier Transform Infrared (FTIR) Spectroscopy, X-ray Powder Diffraction (XRD), Dynamic Light Scattering (DLS), Scanning Electron Microscopy (SEM), Release these from SP-PNPs was investigated vitro at both physiological acidic pH, kinetic models employed assess mechanism drug release. against cells (HepG2) also evaluated. FTIR XRD analyses revealed that encapsulated amorphous state, no observed chemical interactions among or excipients. Assessment release pH 5 7.4 showed loaded 0.5 % PVA released sustained manner, unlike pure drugs, which exhibited relatively fast spherical, had average size 224 nm, encapsulation efficiency (SORA ∼ 82 %, 79 %), well superior cytotoxicity compared monotherapy vitro. These results suggest combining may be effective set comprehensive vivo study evaluate safety novel formulation murine model.

Language: Английский

---

Advances in Microfluidic‐Based Core@Shell Nanoparticles Fabrication for Cancer Applications

Advanced Healthcare Materials, Journal Year: 2024, Volume and Issue: unknown

Published: May 13, 2024

Current research in cancer therapy focuses on personalized therapies, through nanotechnology-based targeted drug delivery systems. Particularly, controlled release with nanoparticles (NPs) can be designed to safely transport various active agents, optimizing specific organs and tumors, minimizing side effects. The use of microfluidics (MFs) this field has stood out against conventional methods by allowing precise control over parameters like size, structure, composition, mechanical/biological properties nanoscale carriers. This review compiles applications the production core-shell NPs (CSNPs) for therapy, discussing versatility inherent microchannel and/or micromixer setups showcasing how these utilized individually or combination, as well technology allows development new advances more efficient fabrication nanoformulations. Recent biological studies have achieved an effective, safe, otherwise unreliable encapsulants such small interfering RNA (siRNA), plasmid DNA (pDNA), cisplatin a result precisely tuned nanocarriers, showing that is paving way innovative strategies nanofabrication, characterized continuous high reproducibility. Finally, analyzes technical, biological, technological limitations currently prevent from becoming standard.

Language: Английский

---

Recent advances in polymeric nanoparticles for the treatment of hepatic diseases

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: Jan. 24, 2025

The liver performs crucial roles in energy metabolism, detoxification, and immune regulation. Hepatic diseases, including hepatitis, fibrosis, cancer, have posed a significant threat to global health, emphasizing the critical need for development of novel effective treatment approaches. Nanotechnology, an emerging technology, has been extensively researched medicine. Among many types nanomaterials, polymeric nanoparticles (NPs) are widely used drug delivery systems. Compared traditional therapies, they offer advantages disease by improving outcomes reducing side effects. This review introduced discussed application natural polymers synthetic their management. Furthermore, this paper reviewed -mainly chitosan (CS), hyaluronic acid (HA), polyethylene glycol (PEG) poly (lactic-co-glycolic acid) (PLGA)-in treatment, focusing on use various systems pure bioactive compounds origin, drugs, nucleic acids, peptides, others. Finally, challenges future perspectives NPs were provide guidance further research directions, with aim promoting clinical nanotherapeutics treating hepatic diseases.

Language: Английский

---

Research progress of sorafenib drug delivery system in the treatment of hepatocellular carcinoma: An update

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 177, P. 117118 - 117118

Published: July 14, 2024

Hepatocellular carcinoma (HCC) is one of the most prevalent malignant tumors in contemporary era, representing a significant global health concern. Early HCC patients have mild symptoms or are asymptomatic, which promotes onset and progression disease. Moreover, advanced insensitive to chemotherapy, making traditional clinical treatment unable block cancer development. Sorafenib (SFB) first-line targeted drug for with anti-angiogenesis anti-tumor cell proliferation effects. However, efficacy SFB constrained by its off-target distribution, rapid metabolism, multi-drug resistance. In recent years, nanoparticles based on variety materials been demonstrated enhance targeting therapeutic against HCC. Concurrently, advent joint delivery systems has furnished crucial empirical evidence reversing This review will summarize application nanotechnology field over past five years. It focus research progress combined multiple modalities treatment.

Language: Английский

---

Lipid core-chitosan shell hybrid nanoparticles for enhanced oral bioavailability of sorafenib

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: 299, P. 140030 - 140030

Published: Jan. 21, 2025

Language: Английский

---

Knowledge structure and dynamic evolution of nanomedicine in liver cancer research: a scientometric analysis and visualization

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 26, 2025

Nanomedicine has received much attention for its potential applications in the diagnosis and treatment of liver cancer. However, no bibliometric evaluation been conducted to present an assessment scientific progress field. The aim this study is comprehensively catalog cooperation influence journals, countries, institutions, authors field nanomedicine cancer from perspective bibliometrics, evaluate clustering evolution knowledge structure, uncover hot topics emerging themes. Articles reviews related were retrieved Web Science Core Literature Library using Topic Search. #1 T= ("Hepatic Neoplasm*" OR "Liver Neoplasm" Cancer*" "Hepatocellular "Hepatic Cancer*"), #2 "nano*", search strategy set as AND limited Citation Index Expanded database source, with limitation publication types language/time. Bibliometric studies CiteSpace VOSviewer. 2,648 articles included 2000 2024. number regarding showed increasing trend. Analysis most productive journals shows that are specialized nanoscience nanotechnology, pharmacology pharmacy, chemistry multidisciplinary. These publications mainly come 8,782 institutions 297 countries led by China United States America. Shao D published papers among publications, while Jemal A had co-citations. macroscopical sketch micro-representation whole realized through co-citation analysis. Hepatocellular carcinoma, targeted delivery, sorafenib nanoparticles, others current developing areas study. keywords "nanocrystals," "biodistribution," "particles" also may be focus new trends future research. In study, bibliometrics visual methods used review research comprehensively. article will help scholars gain a better understanding dynamic point directions

Language: Английский

---

Engineered anti-HER2 drug delivery nanosystems for the treatment of breast cancer

Nanoscale, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Schematic representation of clinical and pre-clinical workflow settings for light controlled release PLGA NPs breast cancer treatment. Created in BioRender.com. Vanni, S. (2025) https://BioRender.com/r11b297.

Language: Английский

---

Cd44 Targeted Delivery of Hyaluronic Acid-Coated Polymeric Nanoparticles Against Colorectal Cancer

Nanomedicine, Journal Year: 2023, Volume and Issue: 18(23), P. 1613 - 1634

Published: Oct. 1, 2023

To develop hyaluronic acid (HA)-coated poly-lactic-co-glycolic (PLGA)-polysarcosine (PSAR) coupled sorafenib tosylate (SF) polymeric nanoparticles for targeted colon cancer therapy.

Language: Английский

---

Sorafenib Encapsulated Poly(ester amide) Nanoparticles for Efficient and Biosafe Prostate Cancer Therapy

ACS Biomaterials Science & Engineering, Journal Year: 2024, Volume and Issue: 10(7), P. 4336 - 4346

Published: June 8, 2024

Prostate cancer (PCa) with a high incidence worldwide is serious threat to men's health. Despite the continuous development of treatment strategies for PCa in recent years, long-term prognosis patients still poor. Hence, discovery and novel, secure, efficient therapeutic approaches hold significant clinical significance. Although sorafenib (SOR) displays potential as option PCa, its efficacy hindered by drug resistance, limited water solubility, rapid metabolism. Therefore, we proposed prepare nanoparticles (named SOR@8P4 NPs) utilizing phenylalanine-based poly(ester amide) polymer (8P4) carrier enhance solubility stability SOR improve targeting bioavailability. NPs had showed acid-responsive release at acidic tumor microenvironment. Additionally, demonstrated more remarkable anticancer, antimetastatic, antiproliferative abilities vitro, compared those free drugs. significantly inhibited growth vivo. In summary, delivery system provides new ideas PCa.

Language: Английский

---

Engineered anti-HER2 drug delivery nanosystems for the treatment of breast cancer

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 29, 2024

Abstract Background Breast cancer stands as the primary affecting women and second most prevalent cause of cancer-related fatalities in developed nations. Consequently, there is a pressing demand for advancement therapeutic strategies that can be seamlessly integrated into clinical applications. We investigated effectiveness an encapsulation decoration strategy employing biodegradable biocompatible carriers together with 3D collagen-based culture models. Envisioning use nano delivery systems localized regional release, we explored feasibility light-controlled drug assisted by optical fibers. Materials methods PLGA nanoparticles loaded or decorated trastuzumab were synthesized via double emulsion protocol characterized dynamic light scattering, surface plasmon resonance, transmission electron microscopy, atomic force Fourier transform infrared spectroscopy. In vitro biological evaluation was then performed on HER2-positive breast cell line BT-474, examining effect nanoformulations viability 2D collagen scaffold Cell cycle, apoptosis, morphology distribution protein expression analyzed. Finally, core-offset fiber fabricated particles release studied using batch microfluidic tests. Results discussion The displayed uniform spherical shape, maintaining stability DMEM up to seven days. successful immobilization TZ verified. trials BT-474 cells models revealed encapsulated demonstrated similar superior activity compared free TZ. Notably, functionalized both internally exhibited highest terms viability, increase apoptosis markers, inducing quiescence. This affirms pivotal role preserving integrity enhancing its targeted delivery. Furthermore, propose breakthrough fiber-optic technology less invasive local PLGA-based nanocarriers effectively used practice. Conclusion Our studies lay foundation future advancements alternative tools treatment. integration advanced carriers, fibers, microfluidics opens new possibilities innovative approaches.

Language: Английский

---